PCSK9 inhibitors are mainly used in clinical hyperlipidemia, atherosclerosis (As), and related ischemic cardiovascular diseases with significant effects and can be used as a substitute for statins and ezetimibe [5,6,7,8]. This evidence concerns the gene PCSK9 and atherosclerosis.